Effect of Pegylated Interferon alfa-2a plus Adefovir in the treatment of chronic hepatitis B with genotype D
Phase 3
- Conditions
- Chronic hepatitis B.Chronic viral hepatitis B without delta-agent
- Registration Number
- IRCT138711201155N4
- Lead Sponsor
- Guilan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
Presence of hepatitis B for more than 6 month, ALT more than 1/1 normal upper limit and less than 10 ULN, 1810.000 copies/ml.
Exclusion criteria: Receiving anti neoplasm, anti viral or immunomedulator drugs during 6 months prior to study, previous treatment, coinfection with Hepatitis A,C,D viruses or HIV, Severe dysfunction of liver and kidney, pregnancy, breast feeding, refusing to give informed consent .
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment. Timepoint: 24 week after treatment. Method of measurement: HBV-DNA<200copies/ml measure with PCR.;Response to treatment. Timepoint: 24 week after treatment. Method of measurement: normal level of ALT measure with Biochemical.
- Secondary Outcome Measures
Name Time Method Adverse effects. Timepoint: monthly. Method of measurement: Clinical evaluation and lab tests.